HC Wainwright & Co. Reiterates Neutral on Oramed Pharmaceuticals
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Neutral rating on Oramed Pharmaceuticals (NASDAQ:ORMP).
May 20, 2024 | 11:21 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Neutral rating on Oramed Pharmaceuticals.
The reiteration of a Neutral rating suggests that the analyst does not see significant upside or downside potential in the short term. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100